A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516333-12-00

Acronym

ES2B-C001-S01

Enrollment

Registered

2024-12-02

Start date

2024-12-16

Completion date

Unknown

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive patients under HER2 maintenance therapy (metastatic or locally advanced, unresectable)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026